Novartis Hedges Its Bet On Fingolimod In MS
This article was originally published in The Pink Sheet Daily
Executive Summary
Submission of backup compound would come three years after filing of initial candidate.
You may also be interested in...
Good News, Bad News For Novartis' Oral MS Drug, But REMS Could Help
Novartis' fingolimod, which could become the first oral treatment for relapsing-remitting multiple sclerosis, recently beat Biogen Idec's Avonex in a head-to-head Phase III trial. The bad news for Novartis is that a handful of severe safety signals, spotted in Phase II, recurred in this most recent trial of the drug
Good News, Bad News For Novartis' Oral MS Drug, But REMS Could Help
Novartis' fingolimod, which could become the first oral treatment for relapsing-remitting multiple sclerosis, recently beat Biogen Idec's Avonex in a head-to-head Phase III trial. The bad news for Novartis is that a handful of severe safety signals, spotted in Phase II, recurred in this most recent trial of the drug
Good News, Bad News For Novartis’ Oral MS Drug, But REMS Could Help
Tysabri’s REMS could prove to be a model for drugs with serious safety signals.